Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America (Q33890337)

29 July 2017

Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America (English)

1 reference

29 July 2017

1

Roberto Giugliani

1 reference

29 July 2017

Martha Luz Solano Villarreal

2

1 reference

29 July 2017

C Araceli Arellano Valdez

3

1 reference

29 July 2017

Antonieta Mahfoud Hawilou

4

1 reference

29 July 2017

Norberto Guelbert

5

1 reference

29 July 2017

Luz Norela Correa Garzón

6

1 reference

29 July 2017

Ana Maria Martins

7

1 reference

29 July 2017

Angelina Acosta

8

1 reference

29 July 2017

Juan Francisco Cabello

9

1 reference

29 July 2017

Aída Lemes

10

1 reference

29 July 2017

Mara Lucia Schmitz Ferreira Santos

11

1 reference

29 July 2017

Hernán Amartino

12

1 reference

29 July 2017

language of work or name

1 reference

1 June 2014

1 reference

Genetics and Molecular Biology

29 July 2017

1 reference

29 July 2017

37

1 reference

29 July 2017

315-329

1 reference

29 July 2017

2

1 reference

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Biomarkers for the mucopolysaccharidoses: discovery and clinical utility.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Natural progression of neurological disease in mucopolysaccharidosis type II.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Transplant outcomes in mucopolysaccharidoses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Novel treatments and future perspectives: outcomes of intrathecal drug delivery.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Multidisciplinary management of Hunter syndrome.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Lysosomal disorders: from storage to cellular damage

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Mucopolysaccharidosis type II in females: case report and review of literature.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Prevalence of lysosomal storage diseases in Portugal

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).

5 July 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Mucopolysaccharidosis type II in females and response to enzyme replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Long-term follow-up following bone marrow transplantation for Hunter disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Initial report from the Hunter Outcome Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Hearing loss in Hunter's syndrome--mucopolysaccharidosis II.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4094607

Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)

29 October 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Heparin cofactor II–thrombin complex: A biomarker of MPS disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1415-47572014000300003

Intravenous enzyme replacement therapy: better in home or hospital?

21 January 2018

1 reference

12 December 2020

Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with selected inherited lysosomal storage diseases

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up

1 reference

12 December 2020

Mucopolysaccharidosis type II--genotype/phenotype aspects

1 reference

12 December 2020

Clinical practice guidelines for pediatric constipation

1 reference

12 December 2020

The oral signs of Hurler-Hunter syndrome: report of four cases

1 reference

12 December 2020

Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders

1 reference

12 December 2020

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

1 reference

12 December 2020

[Guideline for diagnosis, follow-up and treatment of mucopolysaccharidoses type II or Hunter disease]

1 reference

12 December 2020

Idursulfase for the treatment of mucopolysaccharidosis II

1 reference

12 December 2020

Bone marrow transplantation for Sanfilippo disease type B

1 reference

12 December 2020

10.1590/S1415-47572014000300003

Identifiers

DOI

1 reference

release_3udwnthtxfesjpiaradid4gtqa

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3udwnthtxfesjpiaradid4gtqa

24 November 2022

mapped directly with Wikidata item

PMCID

4094607

1 reference

29 July 2017

1 reference